The study compared the European Union system for biosimilar introduction to that of the United States and evaluated the savings that would have arisen from the presence of multiple biosimilars of Humira.
Fluvastatin sodium ER tablets had a market value of approximately $10 million for the 12 months ended May 2021, although actual generic market values are expected to be lower, according to IQVIA.